Macular Degeneration Trial, Recruiting (NCT05558059)

Macular Degeneration Trial, Recruiting NCT05558059 Sponsor: Duke University Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT05558059 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

A healthcare provider who knows about the study's protocol has agreed that the study team may contact the infant's parent or legal guardian
The infant's parent or legal guardian is willing and able to give consent for the infant to take part in the study
The infant meets the American Academy of Pediatrics guidelines for retinopathy of prematurity (ROP) eye screening, and is less than 34 weeks and 6 days gestational age at the time of the first visit

Who may not be able to join:

The parent or legal guardian is unwilling or unable to give consent for the infant to participate
The infant has a health or eye condition that would prevent a standard eye examination or retinal imaging from being performed (for example, a cloudy cornea, such as seen with Peter's anomaly, or a cataract)
The infant has a health condition, other than being born prematurely, that seriously affects brain development (for example, anencephaly) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xi Chen, MD, Duke University

Phone: (919) 684-8434

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05558059

Sponsor: Duke University

Phase: Not Applicable

Status: Recruiting

Condition: Macular Degeneration

Trial contact: (919) 684-8434

More information: https://clinicaltrials.gov/study/NCT05558059

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

A healthcare provider who knows about the study's protocol has agreed that the study team may contact the infant's parent or legal guardian
The infant's parent or legal guardian is willing and able to give consent for the infant to take part in the study
The infant meets the American Academy of Pediatrics guidelines for retinopathy of prematurity (ROP) eye screening, and is less than 34 weeks and 6 days gestational age at the time of the first visit

Who may not be able to join:

The parent or legal guardian is unwilling or unable to give consent for the infant to participate
The infant has a health or eye condition that would prevent a standard eye examination or retinal imaging from being performed (for example, a cloudy cornea, such as seen with Peter's anomaly, or a cataract)
The infant has a health condition, other than being born prematurely, that seriously affects brain development (for example, anencephaly) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Duke University

Registry

ClinicalTrials.gov

Start date

3 October 2024

Est. completion

31 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in vascular density of intermediate and deep vascular plexus at the fovea and perifovea

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov